An oral small molecule, adjunct therapy to insulin in patients with type 1 diabetes (T1D).

Phase 3

TTP399
Overview:

vTv’s TTP399 is a novel, oral, small molecule, liver selective glucokinase activator being developed as an adjunct therapy to insulin in patients with T1D to reduce the occurrence of hypoglycemic episodes. TTP399 restores the normal function of the liver in the presence of high glucose by trapping glucose inside liver cells, promotes further glucose uptake for energy and storage, and keeps the liver in a “fed” state to prevent ketone production.   In its phase 2 study with T1D patients, TTP399 showed a 40% reduction in hypoglycemic episodes compared to placebo when used as adjunctive treatment to insulin therapy, as well as meaningful improvement to HbA1C. In April 2021, the FDA granted Breakthrough Therapy designation to TTP399 for the treatment of T1D. This past October, vTv announced results of a mechanistic study of TTP399 in patients with T1D demonstrating no increased risk of ketoacidosis. TTP399 has now been tested in almost 600 subjects and demonstrated a good safety and tolerability profile. TTP399 will be studied in additional clinical trials to be initiated in 2023.

Type 1 diabetes
Metrics:

Over 1.6 million people in the United States have T1D

Estimated projection of 5 million patients in the U.S. by 2050

Relevant Papers:

View all papers

Sources:
https://www.jdrf.org/t1d-resources/about/facts/
https://care.diabetesjournals.org/content/44/11/2449

REASONS
TO BELIEVE

CIN-102 (deudomperidone) is a Dopamine 2/3 antagonist with prokinetic and antiemetic effects.
Phase 2

CIN-102
OVERVIEW:

CinDome’s CIN-102 (deudomperidone) is a molecular improvement of domperidone, a frequently prescribed first line therapy for nausea, vomiting, and gastroparesis outside of the United States. In part due to safety concerns around QT prolongation, domperidone is not approved in the US. CIN-102 was developed as a new chemical entity by the formulation and pharmacology team at CinRx to alter the PK profile for sustained efficacy while significantly reducing cardiac liability.


CinDome has progressed CIN-102 from concept into Phase 2 with favorable PK profile, a negative TQT study, and promising effect on gastric emptying and improvement of nausea and vomiting in subjects with gastroparesis.

GASTROPARESIS
Metrics:

12-16 million patients in the US have symptoms of gastroparesis

>$4B annual prescription market in the US

Currently no chronic treatments available

Sources:
1. Rey E, Choung RS, Schleck CD, Zinsmeister AR, Talley NJ, Locke GR 3rd. Prevalence of hidden gastroparesis in the community: the gastroparesis “iceberg”. J Neurogastroenterol Motil. 2012 Jan;18(1):34-42
2. Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136(4):1225-1233

REASONS
TO BELIEVE

CIN-103 is a novel formulation of phloroglucinol modified to enhance the pharmacokinetic properties to sustain the therapeutic exposure for patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Phase 2

CIN-103
OVERVIEW:

CinPhloro’s CIN-103 is a novel, small-molecule, modified pulsatile-release formulation of phloroglucinol – a phenol-derivative with antispasmodic properties. In pre-clinical studies, CIN-103 has demonstrated to impact intestinal motility, secretion, pain, spasms & inflammation. Phloroglucinol is approved in several countries in Europe for the treatment of gastrointestinal disorders. Employing an extrusion-spheronization process, CinPhloro’s scientific and pharmacology team went through an extensive formulation process to reach a desired pharmacokinetic profile by combining immediate and delayed release technology. CIN-103 has progressed from concept through Phase I Multiple Ascending Dose (MAD) trials demonstrating the desired PK profile. Phase I results demonstrated evidence of enhanced PK release profile based upon the novel CinPhloro formulation as well as decreased GI motility, secretion, pain, spasm and inflammation. CIN-103 will be studied in additional clinical trials to be initiated in 2023.

IBS-D
Metrics:

Prevalence between 10%-15% in North America

Affects approximately 16.2M in the US

Most common reason for a referral to a gastroenterologist

REASONS
TO BELIEVE

CIN-109, CIN-110, CIN-209 and CIN-210 are series of mono and combination therapies for the treatment of obesity.

CIN-109
Phase 1
CIN-110
Pre-Clinical
CIN-209
Pre-clinical
CIN-210
Pre-clinical

CIN-109, CIN-110, CIN-209, CIN-210
OVERVIEW:

CinFina’s portfolio of obesity therapeutics include mono- and combination- therapies designed to support healthy weight loss. The portfolio was licensed from Janssen Pharmaceuticals and includes:

OBESITY
Metrics:

41.9% of the US population is considered obese (30≤ BMI < 40)

For every 5kg/m2 BMI increment above the range of 22.5-25kg/m2, there is a 30% increase in overall mortality

Sources:
Bryan, Stierman, et al. NHSR 158. National Health and Nutrition Examination Survey 2017–March 2020 Pre-Pandemic Data Files. 14 June 2021, stacks.cdc.gov/view/cdc/106273.

Morgan Stanley

Fujioka, K, et al. “The Relationship between Early Weight Loss and Weight Loss at 1 Year with Naltrexone ER/Bupropion ER Combination Therapy.” International Journal of Obesity, vol. 40, no. 9, 22 June 2016, pp. 1369–1375, 10.1038/ijo.2016.67. Accessed 15 Apr. 2020.

REASONS
TO BELIEVE

CIN-108 is a small molecule inhibiting defective in cullin neddylation 1 (DCN1) from binding in the pocket where is it necessary to promote neddylation and interfere with the progression of multiple solid tumors.

Pre-clinical

CIN-108
OVERVIEW:

CinSano’s CIN-108, a small molecule compound that inhibits a novel, well-studied oncogene target, DCN1, which is amplified in multiple cancer types and correlates with more severe prognosis. Licensed in 2021 by CinRx, the goal for CIN-108 is to disrupt the neddylation pathway by preventing binding of DCN1 to the pocket necessary for it to promote neddylation. The CIN-108 compound series is currently being optimized. Regulatory and human clinical development milestones are planned for 2023.

Solid Tumor
Metrics:

Represent approximatively 90% of adult human cancers

Sources:

American Cancer Society

REASONS
TO BELIEVE

Retromer Therapeutics is developing novel therapeutics to treat neurodegenerative diseases.
Pre-clinical

OVERVIEW:

Retromer Therapeutics is a pre-clinical stage biotech company pioneering a new class of therapeutics to treat neurodegenerative diseases by resorting the function of the endolysosmal trafficking system with preclinical programs in neurodegenerative disorders including Alzheimer’s disease.

Type 1 diabetes
Metrics:

In the United States, as many as 6.2 M people may have Alzheimer’s disease.

Occur when nerve cells in the brain or peripheral nervous system lose function over time and ultimately die.

Sources:
Medline, National Institute of Environmental Health Science, Alzheimer’s Disease Association, Parkinson’s Foundation

REASONS
TO BELIEVE

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES